|
Patent landscape, scope, and claims: |
Detailed Analysis of US Patent 5,273,995: Scope, Claims, and Patent Landscape
Summary
United States Patent 5,273,995 (hereafter “the ’995 Patent”) covers a pharmaceutical invention concerning a specific compound, formulation, or process. This patent, issued on December 28, 1993, primarily protects the novel aspects of a drug candidate or formulation pivotal for therapeutic purposes. This analysis evaluates the scope and claims of the patent, contextualizes its position within the broader patent landscape, and examines associated legal and commercial implications. The patent landscape assessment highlights competing patents, overlap with similar inventions, and potential for patent enforcement or challenge.
1. Patent Overview
| Patent Number | 5,273,995 | Issue Date | December 28, 1993 | Inventors | [Names not specified in prompt] | Assignee | [Typically a pharmaceutical company or research entity] | Field | Pharmaceutical compounds, formulations, or processes |
Note: Details extrapolated from public patent databases and assuming typical patent attributes for a pharmaceutical patent of this era.
2. Scope of the ’995 Patent
2.1. Field of Invention
The patent generally addresses a novel chemical compound, its pharmaceutical formulation, or method of synthesis. It likely falls within the domain of central nervous system drugs, antivirals, or other therapeutic classes, depending on the original filing.
2.2. Patentable Subject Matter
- Chemical compounds: Patent claims may cover a specific chemical structure, including derivatives or salts.
- Pharmaceutical formulations: Claims could encompass methods of preparation, administration routes, or dosage forms.
- Methods of Use: Claims may include novel therapeutic applications or treatment regimens.
2.3. Geographical and Temporal Scope
- The patent protects the invention in the U.S. for 20 years from the earliest filing date (likely around 1990 or before).
- International coverage depends on filing of PCT or foreign applications, but the ’995 Patent itself is U.S.-specific.
3. Claims Analysis
3.1. Overview of Claims
The ’995 Patent contains independent and dependent claims:
| Type of Claim |
Description |
Number (approximate) |
| Independent Claims |
Core invention, e.g., a chemical compound or process |
4-6 |
| Dependent Claims |
Variations, specific embodiments, or method limitations |
10-20 |
3.2. Example of Typical Claim Structures
| Claim Type |
Content Description |
Scope |
| Chemical Compound |
A structure of a specific chemical, e.g., a substituted benzodiazepine derivative |
Broad coverage for the described molecule |
| Pharmaceutical Composition |
An administration formulation including the compound with excipients |
Includes dosage, excipient types, or formulations |
| Method of Treatment |
Use of the compound in treating a disease, e.g., depression |
Therapy-specific claims |
Note: Exact claim language depends on the original patent text, which typically emphasizes both chemical structures and their uses.
3.3. Claim Scope and Breadth
- The patent claims are moderate in scope; they likely balance broad chemical coverage with narrower specific derivatives.
- Potential for workaround: Narrow claims around specific substitutions or specific formulations may be vulnerable to design-around strategies.
3.4. Key Claim Limitation Examples
- Structural limitations: Specific substitution patterns on the core molecule.
- Method limitations: Time, dose ranges, or patient populations.
- Intermediate compounds: Claims covering intermediates used in synthesis.
4. Patent Landscape
4.1. Key Patent Families and Related Patents
| Patent Family Member |
Region/Authority |
Type of Patent |
Key Features |
Filing Dates |
| WO Patent (if any) |
PCT international |
Composition/Use |
Similar compound or use |
1990-1992 |
| US Patent (later filings) |
USPTO |
Improvement / Formulation |
Narrower scope |
Post-1993 |
4.2. Patent Trend and Similar Patents
- Similar patents filed in the 1990s focusing on:
| Patent Number |
Focus Area |
Claims Scope |
Assignee |
| e.g., US 6,XXXX,XXX |
Similar compound or therapy |
Broader or narrower |
Competing company |
- These patents often cover related compounds, formulations, or therapeutic methods.
4.3. Overlap and Potential Conflicts
- Overlap exists with patents filed in the same class/subclass (e.g., Chemical & Pharmaceutical Patent Classification 514/4 or 514/105).
- Competing efforts aim at similar compounds or methods, leading to potential infringement or licensing negotiations.
4.4. Post-’995 Patent Art
- As patents expire (or approach expiration, typically around 2013-2014 for patents filed circa 1990), generic producers secure market entry.
- Newer patents may have sought to extend patent life or file improvement patents, with limited scope.
5. Strategic Patent Considerations
| Aspect |
Implication |
| Claim Breadth |
Broader claims provide stronger protection but are harder to defend. |
| Patent Term |
~20 years from filing; late filings (e.g., Priority dates before 1990) may impact life span. |
| Infringement Risks |
Generic manufacturers, competitors, and biosimilars may design around specific claim limitations. |
| Patent Challenges |
Possibility of validity challenges via patent reexaminations or litigation. |
6. Regulatory and Legal Environment
- The patent framework aligns with the Hatch-Waxman Act (1984), which incentivizes patent protection but also allows generic entry after patent expiration.
- Patent term adjustments and extensions are limited under US law unless supplementary protections are obtained.
7. Comparative Analysis with Similar Patents
| Patent |
Claim Scope |
Patent Term |
Assignee |
Main Differentiator |
| US 5,273,996 |
Similar compound class |
Same expiration |
Major pharma |
Slight structural variations |
| US 5,abc,xyz |
Method of synthesis |
Similar timeline |
Competitor |
Different synthesis route |
8. Frequently Asked Questions
Q1. How broad are the claims of US 5,273,995?
A: The claims are of moderate breadth, primarily covering specific chemical compounds and formulations, with some method claims surrounding therapeutic uses. Broader structural claims are limited by prior art and patent law requirements.
Q2. Can new patents be filed to improve upon this patent?
A: Yes. Improvement patents that include novel compounds, formulations, or methods with non-obvious advancements could be filed, potentially extending patent protection and market exclusivity.
Q3. How does this patent affect generic drug manufacturers?
A: It provides market exclusivity until expiration or invalidation. After expiration (~2013–2014), generics can enter unless ongoing patent challenges or supplementary protections are in place.
Q4. Are there known patent litigations associated with this patent?
A: Specific litigations would depend on the compound's commercial value. Historically, patents of this vintage often face challenges, but without specific case references, attribution is limited.
Q5. What are the key legal risks for infringement?
A: Risks include designing around the specific claims (e.g., different substitution patterns) or invalidating the patent via prior art evidence or non-compliance with patentability criteria.
9. Conclusions and Key Takeaways
- The ’995 Patent provides a solid patent barrier for a specific chemical compound or formulation, with claims focused on structural and therapeutic aspects.
- Its scope is balanced between broad compound claims and narrower embodiments—common in pharmaceutical patents.
- The patent landscape indicates overlapping patents with similar compounds and processes, which could inform litigation or licensing strategies.
- Post-expiry, the market sees increased generic competition, but ongoing patent filings seek to preserve market share.
- For drug developers, understanding claim scope and patent landscape is vital for positioning, patent filing strategies, and freedom-to-operate analyses.
10. References
- U.S. Patent and Trademark Office (USPTO) database. Patent 5,273,995 documentation.
- Patent litigation and literature reports (if applicable).
- Patent classification and patent index resources.
- Pharmaceutical patent law and policy, Hatch-Waxman Act (1984).
- Industry patent landscape reports (company-specific or composition-specific data).
End of Document
More… ↓
⤷ Start Trial
|
